PSTV 8-K — Smart Summary

78% reduction

Plus Therapeutics, Inc. discloses that on February 9, 2026, the Compensation Committee approved discretionary cash bonuses for Named Executive Officers for Fiscal Year 2025, and provides an updated Summary Compensation Table including those bonus amounts and total compensation figures.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

Executive Compensation

Marc H. Hedrick, M.D. (President and CEO) — FY2025: base salary $585,000; option awards $3,531,841; restricted stock awards $1,100,647; non-equity incentive plan compensation (discretionary cash bonus) $305,663; all other compensation $43,581; total $5,566,732. FY2024: base salary $556,400; option awards $335,348; non-equity incentive plan compensation $321,321; all other compensation $47,216; total $1,260,285
Andrew Sims (CFO) — FY2025: base salary $390,000; option awards $810,388; restricted stock awards $264,154; non-equity incentive plan compensation (discretionary cash bonus) $149,175; all other compensation $17,562; total $1,631,279. FY2024: base salary $372,750; option awards $74,758; non-equity incentive plan compensation $156,555; all other compensation $17,053; total $621,116
Norman LaFrance, M.D. (Former CMO) — FY2025: all compensation categories $0; total $0. FY2024: base salary $258,446; all other compensation $27,466; total $285,912

Departures

Former Chief Medical Officer Norman LaFrance, M.D. — stepped down from his position as Chief Medical Officer on June 11, 2024; received $0 in total compensation for Fiscal Year 2025

§ MORE SUMMARIES